What type of study is this?

This is a Human Clinical Trial study.

October 3, 2025Open Access

Supplementary Figure S8 from Optimization of a Novel 2 + 2 BCMA × CD3 Bispecific Antibody for Minimized Cytokine Release and Potent Efficacy

View Full Paper

Ask AI

Bookmark

Minimized cytokine release highlights improved safety profiles of the antibody in treatment scenarios.
The phase I clinical trial registered under NCT04735575 escalated doses to evaluate therapeutic efficacy and safety.
The novel bispecific antibody combines BCMA and CD3 targeting to enhance immune response against cancer cells.
Findings indicate a promising approach to improve treatment outcomes while maintaining manageable side effects.

Phase I clinical trial assesses a bispecific antibody's efficacy while minimizing cytokine release, suggesting enhanced safety protocols.

Illustration of dosing schedule and dose escalation for the phase I clinical trial (NCT04735575).

No takes yet. Share an insight, caveat, or question.

Wu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase I clinical trial assesses a bispecific antibody's efficacy while minimizing cytokine release, suggesting enhanced safety protocols.

Illustration of dosing schedule and dose escalation for the phase I clinical trial (NCT04735575).